SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Papi Alberto)
 

Sökning: WFRF:(Papi Alberto) > Incidence of oral t...

Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids : Effect of drug, dose, and device

Dekhuijzen, P. N Richard (författare)
Radboud University Nijmegen
Batsiou, Maria (författare)
Cambridge Research Support Ltd
Bjermer, Leif (författare)
Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
visa fler...
Bosnic-Anticevich, Sinthia (författare)
University of Sydney
Chrystyn, Henry (författare)
Plymouth University
Papi, Alberto (författare)
University of Ferrara
Rodríguez-Roisin, Roberto (författare)
University of Barcelona
Fletcher, Monica (författare)
Education for Health
Wood, Lucy (författare)
Observational and Pragmatic Research Institute Pte Ltd
Cifra, Alessandra (författare)
Observational and Pragmatic Research Institute Pte Ltd,Cambridge Research Support Ltd
Soriano, Joan B. (författare)
Autonomous University of Madrid
Price, David B. (författare)
University of Aberdeen
visa färre...
 (creator_code:org_t)
Elsevier BV, 2016
2016
Engelska 10 s.
Ingår i: Respiratory Medicine. - : Elsevier BV. - 0954-6111. ; 120, s. 54-63
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background and aims Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device. Methods We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long-acting bronchodilators or FDC ICS/LABA therapy. We then compared different combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and fluticasone propionate/salmeterol xinafoate [FP/SAL]) and devices (DPI and pMDI). Results Patients prescribed FDC ICS/LABA had significantly greater odds of experiencing oral thrush than those prescribed long-acting bronchodilators alone (adjusted OR 2.18 [95% CI 1.84–2.59]). Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush compared with FP/SAL DPI (OR 0.77 [0.63–0.94]) when allowing for differences in prescribed doses between the drugs. A significantly smaller proportion of patients developed oral thrush in the FP/SAL pMDI arm than in the FP/SAL DPI arm (OR 0.67 [0.55–0.82]). Additionally, in the FP/SAL cohort (both DPI and pMDI), increased risk of oral thrush was significantly associated with high ICS daily dose (OR 1.97 [1.22–3.17] vs low daily dose). Conclusions ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be more protective against oral thrush.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Nyckelord

Chronic obstructive pulmonary disease
Dry powder inhaler
Inhaled corticosteroid
Oral candidiasis
Pressurised metered-dose inhaler
Spacer

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy